Eyelid; WoundNCT07234292
Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery
An observational study of Eyelid; Wound, run by Laboratoires Thea at 1 site in France.
Trial summary
The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis). The participant will be asked to use Blephaderm twice a day. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Eyelid; Wound
- What is being tested?
- Cosmetic: Blephaderm
- How many people
- 12 participants
- Where
- 1 siteFrance
- Study dates
- 30 Oct 2025to 19 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A total of 30 patients undergoing blepharoplasty or ptosis surgery
Who may be able to join
- Age ≥ 18 years old
- Patients planning a blepharoplasty or a ptosis surgery in at least one eye.
- Patient affiliated to a health social security system
- Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.
Who cannot join
- In terms of population:
- Pregnant or nursing woman or planning a pregnancy during the study.
- Patient who had been deprived of their freedom by administrative or legal decision
- Minor patient.
- Major patient who is under guardianship or who is not able to express his non opposition.
- Patient suspected to be non-compliant according to the investigator's judgment.
Show all 25Show fewer
- Patient enrolled in another clinical trial or which exclusion period is not over.
- In terms of associated pathology
- Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk.
- Patient suffering from a severe or progressive disease.
- Patient with known or suspected hypersensitivity to one of the components of the product.
- Related to previous or ongoing treatment
- Patient undergoing a topical treatment on the test area or a systemic treatment.
- Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation.
- Patient under immunosuppressive therapy
- Patient under bisphosphonate therapy
- Patient having Type 1 diabetes
- Patient having atopic or eczema skin
- In terms of lifestyle
- Intensive exposure to sunlight or UV-rays foreseen during the study.
- Patient planning to change her/his life habits during the study.
- Patient with an excessive consumption of alcohol and/or tobacco defined as:
- an excessive consumption of alcohol: Drinking more than
- 4 units a day for adult men and more than 2 units a day for adult women,
- an excessive consumption of tobacco: ≥15-20 Cigarettes Per Day (CPD).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Patient Satisfaction With a New Preservative-free Eyelid Cream as a Complementary Care in Post-eyelid Surgery: The ADMIRE Study
The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis).
The participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.
- Conditions
- Eyelid; Wound
- Being tested
- Cosmetic: Blephaderm
- Medical subject headings
- Wounds and Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cosmetic: BlephadermOther
Preservative free eyelid cream: Aqua (water), oleyl erucate, trehalose, sodium acrylates copolymer, lecithin, Ophiopogon japonicus root extract, hydrolyzed hyaluronic acid, maltodextrin, tocopherol, sodium hydroxide, phytic acid, Glycine soja (soybean) oil, Helianthus annuus seed oil.
| Study group | Role | What they receive |
|---|---|---|
| Group receiving Blephaderm | Not described Receives: Other: Cosmetic: Blephaderm |
What is being measured
The primary outcome is the main question the study is designed to answer.
global satisfaction of the patient on eyelid comfort after 3 months of Bllephaderm® use, assessed at M4, using a VAS from 0 (unsatisfied) to 10 (very satisfied).
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2025
- Study start30 Oct 2025
- Primary completion19 Jun 2026
- Study completion19 Jun 2026
Why it stopped: The premature termination of the study is due to a strategic decision by the sponsor and is not related to any safety concerns for study participants.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Eyelid; WoundStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Laboratoires Thea
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07234292
- Sponsor's protocol ID
- LT10100-001
- Status last verified
- Oct 2026
- First submitted
- 14 Nov 2025
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Patient Satisfaction With a New Preservative-free Eyelid Cream as a Complementary Care in Post-eyelid Surgery: The ADMIRE Study
- ClinicalTrials.gov ID
- NCT07234292
- Acronym / sponsor ID
- LT10100-001
- Conditions
- Eyelid; Wound
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: The premature termination of the study is due to a strategic decision by the sponsor and is not related to any safety concerns for study participants.
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Laboratoires TheaIndustry (pharma, biotech, devices)
- Study start
- 30 Oct 2025 (actual)
- Primary completion
- 19 Jun 2026 (actual)
- Study completion
- 19 Jun 2026 (actual)
- First posted
- 18 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis).
The participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group receiving Blephaderm | – | Other: Cosmetic: Blephaderm |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A total of 30 patients undergoing blepharoplasty or ptosis surgery
Key inclusion criteria (4 listed)
- Age ≥ 18 years old
- Patients planning a blepharoplasty or a ptosis surgery in at least one eye.
- Patient affiliated to a health social security system
- Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.
Key exclusion criteria (25 listed)
- Pregnant or nursing woman or planning a pregnancy during the study.
- Patient who had been deprived of their freedom by administrative or legal decision
- Minor patient.
- Major patient who is under guardianship or who is not able to express his non opposition.
- Patient suspected to be non-compliant according to the investigator's judgment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cosmetic: BlephadermPreservative free eyelid cream: Aqua (water), oleyl erucate, trehalose, sodium acrylates copolymer, lecithin, Ophiopogon japonicus root extract, hydrolyzed hyaluronic acid, maltodextrin, tocopherol, sodium hydroxide, phytic acid, Glycine soja (soybean) oil, Helianthus annuus seed oil. | Other | Group receiving Blephaderm |
Primary outcome
global satisfaction of the patient on eyelid comfort after 3 months of Bllephaderm® use, assessed at M4, using a VAS from 0 (unsatisfied) to 10 (very satisfied).
Time frame: 3 months
Results and safety
The study was stopped early (reason given: The premature termination of the study is due to a strategic decision by the sponsor and is not related to any safety concerns for study participants.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
Related trials for Eyelid; Wound
Not yet recruiting
A Trial to Evaluate Two Ectropion Preventive Measures Using the Subciliary Approach in Orbital Fracture Surgery.
Orbital Fractures, Orbital Floor Fractures
RecruitingPhase 4
Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
Dry Eye, Meibomian Gland Dysfunction
Not yet recruiting
Eyelid Taping Alone Versus Taping With Lubricant Eye Drops for Perioperative Corneal Protection
Corneal Injury, Exposure Keratopathy
Not yet recruiting
Management and Outcomes of Traumatic Eyelid Injuries in Assiut University Hospital
Traumatic Eyelid Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Eyelid; Wound, run by Laboratoires Thea at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The premature termination of the study is due to a strategic decision by the sponsor and is not related to any safety concerns for study participants.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
global satisfaction of the patient on eyelid comfort after 3 months of Bllephaderm® use, assessed at M4, using a VAS from 0 (unsatisfied) to 10 (very satisfied). (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.